Literature DB >> 8160376

Visual field deficits in early age-related macular degeneration.

M J Tolentino1, S Miller, A R Gaudio, M A Sandberg.   

Abstract

Patients with early age-related macular degeneration (AMD) may retain good visual acuity but experience distortion and other qualitative visual changes. The purpose of the present study was to determine whether deficits of form recognition, as well as of light sensitivity, were related to retinal pigment epithelial (RPE) atrophy and/or drusen. We assessed form recognition deficits by the Amsler grid and by a perimetric test of letter recognition and sensitivity deficits by the macular threshold test of the Humphrey Field Analyzer in 59 patients with AMD and visual acuities of 20/40 or better. The number of defects on each test was compared with the area of RPE atrophy and with the area of drusen determined from fundus photographs. Multiple regression analyses based on ordinal data revealed that the number of visual field defects by each test was significantly correlated with the area of atrophy, but not with the area of drusen. There was also no significant tendency for a patient with a regional preponderance of drusen to have more impairment in the corresponding visual field. These results suggest that deficits of form recognition, as well as of sensitivity, in patients with early stages of AMD can be attributed to alteration of photoreceptor function associated with RPE atrophy, but not with drusen.

Entities:  

Mesh:

Year:  1994        PMID: 8160376     DOI: 10.1016/0042-6989(94)90099-x

Source DB:  PubMed          Journal:  Vision Res        ISSN: 0042-6989            Impact factor:   1.886


  14 in total

1.  In vivo observation of transient photoreceptor movement correlated with oblique light stimulation.

Authors:  Yiming Lu; Changgeng Liu; Xincheng Yao
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2018-02-20

2.  Multifocal pupillography identifies retinal dysfunction in early age-related macular degeneration.

Authors:  Faran Sabeti; Andrew C James; Rohan W Essex; Ted Maddess
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-08       Impact factor: 3.117

3.  Metamorphopsia and letter recognition.

Authors:  Emily Wiecek; Steven C Dakin; Peter Bex
Journal:  J Vis       Date:  2014-12-01       Impact factor: 2.240

4.  Association assessment of copy number polymorphism and risk of age-related macular degeneration.

Authors:  Julie Sawitzke; Kate M Im; Brittany Kostiha; Michael Dean; Bert Gold
Journal:  Ophthalmology       Date:  2011-12       Impact factor: 12.079

5.  Prevalence and the risk factors for visual impairment in age-related macular degeneration.

Authors:  S Srinivasan; G Swaminathan; V Kulothungan; R Raman; T Sharma
Journal:  Eye (Lond)       Date:  2017-05-26       Impact factor: 3.775

6.  Measuring visual function in age-related macular degeneration with frequency-doubling (matrix) perimetry.

Authors:  Andrew John Anderson; Chris A Johnson; John S Werner
Journal:  Optom Vis Sci       Date:  2011-07       Impact factor: 1.973

Review 7.  Complement in age-related macular degeneration: a focus on function.

Authors:  D T Bradley; P F Zipfel; A E Hughes
Journal:  Eye (Lond)       Date:  2011-03-11       Impact factor: 3.775

8.  Foveal electroretinograms and choroidal perfusion characteristics in fellow eyes of patients with unilateral neovascular age-related macular degeneration.

Authors:  J F Remulla; A R Gaudio; S Miller; M A Sandberg
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

9.  Colour contrast sensitivity in patients with soft drusen, an early stage of ARM.

Authors:  C Frennesson; U L Nilsson; S E Nilsson
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

10.  Parafoveal letter recognition at reduced contrast in normal aging and in patients with risk factors for AMD.

Authors:  Gesa Astrid Hahn; Andre Messias; Manfred Mackeben; Klaus Dietz; Karin Horwath; Lea Hyvärinen; Markku Leinonen; Susanne Trauzettel-Klosinski
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-08-28       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.